Roche's Tecentriq scores again on a pivotal frontline lung cancer trial, positioning them against Merck, Bristol-Myers
Roche $RHHBY nailed some badly needed success in its late-stage campaign to build a market for its PD-L1 drug Tecentriq today, posting a win for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
